Localization, purification, and biological activity of a new aldosterone-stimulating factor.

Localization, purification, and biological activity of a new aldosterone-stimulating factor. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Localization, purification, and biological activity of a new aldosterone-stimulating factor. Abstract Text:

S Sen,R Valenzuela,R Smeby,E L Bravo,F M Bumpus,

An aldosterone-stimulating factor (ASF) has been isolated from normal human urine and found to be a glycoprotein with a molecular weight of 26,000 daltons. ASF stimulated aldosterone production both in vivo and in vitro. ASF was found to be different from other known aldosterone secretogogues by the use of high performance liquid chromatography (HPLC). The retention time of ASF was different (17.0 minutes) from ACTH (retention time, 28.4 minutes), beta-lipotropin (retention time, 20.5 minutes), and angiotensin II. Proteolytic enzyme digestion and purification of ASF by HPLC yielded a smaller molecule (retention time, 22.0 minutes) with a molecular weight of 4000 daltons. This smaller molecule also stimulated aldosterone production in vitro. This showed that the structural requirement for steroidogenesis may be residing in a smaller molecule. ASF failed to produce hypertension in adrenalectomized rats. By immunofluorescence (using fluorescein conjugated antibodies), ASF was found to be localized in the anterior lobe of the pituitary gland. Data suggest that ASF, a new aldosterone-stimulating hormone that has not been described before, is secreted by the pituitary gland, and the adrenal gland appears to be the target organ for the biological activities.

Localization, purification, and biological activity of a new aldosterone-stimulating factor. Publishing Authors By Initials

S Sen,R Valenzuela,R Smeby,EL Bravo,FM Bumpus,

For similar proteins research abstracts see: proteins research

PUBMED ID PMID:

MEDLINE DATE: 1981 May-Jun

Localization, purification, and biological activity of a new aldosterone-stimulating factor. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Hypertension

VOLUME: 3

Page Numbers: I81-6

Journal Abbreviation: Hypertension

ISSN: 0194-911X

DAY: 19

MONTH: 11

YEAR: 2007

Localization, purification, and biological activity of a new aldosterone-stimulating factor. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7906255

Localization, purification, and biological activity of a new aldosterone-stimulating factor. Keywords Mesh Terms:

KEYWORDS: Proteins

MESH TERMS: pharmacology

Chemical & Substance for Abstract: Localization, purification, and biological activity of a new aldosterone-stimulating factor. Information

Substance Name: Aldosterone

Registry Number: 52-39-1

Grant and Affiliation Information for Localization, purification, and biological activity of a new aldosterone-stimulating factor.

AFFILIATION:

Country: UNITED STATES

AGENCY: United States NHLBI

GRANT: NHLB1-6835

ACRONYM: HL

MEDLINETA: Hypertension

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Localization, purification, and biological activity of a new aldosterone-stimulating factor Related Publications

• Acute Urinary Infections.
• Cancer of the Prostate: A Report of Thirty-Four Cases Seven And Eight Years after Treatment by Transurethral Resection.
• Idiopathic hyperaldosteronism. A possible role for aldosterone-stimulating factor.
• Inhibition of lignin peroxidase-mediated oxidation activity by ethylenediamine tetraacetic acid and N-N-N'-N'-tetramethylenediamine.
• Iodide oxidation and iodine reduction mediated by horseradish peroxidase in the presence of ethylenediaminetetraacetic acid (EDTA): the superoxide effect.
• Isolation of aldosterone-stimulating factor (ASF) and its effect on rat adrenal glomerulosa cells in vitro.
• Isorenin in dog brain and other tissues.
• Localization, purification, and biological activity of a new aldosterone-stimulating factor.
• Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
• Patients' perceptions of the effectiveness of guided imagery and progressive muscle relaxation interventions used for cancer pain.
• Prostatic Obstruction-Development of Its Surgical Treatment: Part I.
• Prostatic Obstruction-Development of Its Surgical Treatment: Part II.
• Steroidogenic characteristics of a new aldosterone-stimulating factor (ASF) isolated from normal human urine.
• Steroidogenic properties of a new aldosterone-stimulating factor: interaction with angiotensin II and adrenocorticotropin during variations of dietary sodium.
• Urinary Tract Infections: From A General Practice Standpoint: Part I.
• Urinary Tract Infections: From a General Practice Standpoint: Part II.
• What We May Expect from Treatment of Bladder Tumors.